Women, IBS, and Serotonin Antagonism

DiBaise, John K.; Thompson, Jon S.
August 2000
American Journal of Gastroenterology;Aug2000, Vol. 95 Issue 8, p1865
Academic Journal
Discusses research being done on the efficacy and safety of alosetron, a serotonin receptor antagonist, in women with irritable bowel syndrome. Reference to a study by M. Camilleri et al published in the 2000 issue of "Lancet"; Findings of the study.


Related Articles

  • Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome Olden, Kevin; DeGarmo, Ronald G.; Jhingran, Priti; Bagby, Barbara; Decker, Chris; Markowitz, Michael; Carter, Eric // American Journal of Gastroenterology;Dec2002, Vol. 97 Issue 12, p3139 

    OBJECTIVE:The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials. However, the degree to which alosetron fulfills the needs of those suffering from IBS has not been thoroughly...

  • Does alosetron have a place in IBS treatment?  // Reactions Weekly;6/12/2004, Issue 1005, p2 

    Assesses the clinical benefits and risks of the drug alosetron, a selective serotonin 3 receptor antagonist. Efficacy of the drug in treating irritable bowel syndrome; Action taken by GlaxoSmithKline with regard to the reported side effects of the drug; Restrictions within the reintroduction of...

  • The Risk of Ischaemic Colitis in Irritable Bowel Syndrome Patients Treated with Serotonergic Therapies. Lewis, James H. // Drug Safety;2011, Vol. 34 Issue 7, p545 

    Ischaemic colitis (IC) is the most common form of ischaemic injury to the gastrointestinal (GI) tract. IC typically presents with the sudden onset of lower abdominal pain, cramping and rectal bleeding, and is usually self-limited with low morbidity, although it may cause gangrenous or fulminant...

  • Irritable bowel syndrome can have a genetic cause.  // Foods Matter (UK);Feb2009, p16 

    The article focuses on a study by Doctor Beate Niesler and her team at the Heidelberg Institute of Human Genetics in Germany which found that there may be a genetic cause in irritable bowel syndrome. Niesler says that patients with irritable bowel syndrome with diarrhea reflect a higher...

  • Cilansetron. Zimmermann, Anthony E. // Formulary;Feb2005, Vol. 40 Issue 2, p44 

    If approved, cilansetron (Calmactin, Solvay Pharmaceuticals) would be the second selective 5-HT antagonist introduced for the treatment of imtable bowel syndrome (IBS). Based on 2 main clinical trials, cilansetron 2 mg orally 3 times daily appears to be effective in the relief of IBS-D symptoms...

  • Cilansetron: A New Selective Serotonin Type 3 (5-HT3)-Receptor Antagonist for the Treatment of Irritable Bowel Syndrome in Males and Females. Albertson, Brent A. // Hospital Pharmacy;Aug2006, Vol. 41 Issue 8, p761 

    Irritable Bowel Syndrome (IBS) is a significant problem that affects a large proportion of the US population. The past several years have seen advances in our understanding of the pathophysiology associated with IBS and the development of new therapies. Older therapies have few well-designed...

  • Effects of Ramosetron on Gastrointestinal Transit of Guinea Pig. Yoo Mi Park; Young Ju Lee; Young Ho Lee; Tae Il Kim; Hyojin Park // Journal of Neurogastroenterology & Motility;Jan2013, Vol. 19 Issue 1, p36 

    Background/Aims: A selective 5-hydroxytryptamine (5-HT) type 3 receptor antagonist, ramosetron, inhibits stress-induced abnormal defecation in animals and is currently used as a therapeutic drug for irritable bowel syndrome with diarrhea. The aim of this study is to investigate the effect of...

  • Revival of 5-HT3 antagonism as treatment of IBS-D? Barbara, Giovanni // Gut;Oct2014, Vol. 63 Issue 10, p1530 

    The article discusses a research study by K. Garsed and colleagues on the effectiveness of 5-HT serotonin antagonist in the management of inflammatory bowel syndrome with diarrhea (IBS-D). Topics discussed include the key mechanisms of IBS-D pathophysiology, effectiveness of ramosetron in...

  • Lotronex, serotonin inhibitors for IBS win physician support; Novartis, BMS sign promo pact.  // Medical Marketing & Media;Nov2000, Vol. 35 Issue 11, p10 

    Reports on the attributes of alosetron, a drug for irritable bowel syndrome (IBS). Use of serotonin inhibitors for IBS; Agreement between Novartis and Bristol-Myers Squibb Co.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics